AZD-7648

AZD-7648 purchased from MedChemExpress. Usage Cited in: Nucleic Acids Res. 2025 Aug 11;53(15):gkaf767. [Abstract]

Customer Validation
AZD7648 (1 µM; 48 h) showed less cytotoxicity in HSPCs relative to M3814 (2 µM; 48 h).

AZD-7648 purchased from MedChemExpress. Usage Cited in: Theranostics. 2023 Aug 28;13(14):4745-4761. [Abstract]

Customer Validation
Cell growth response at Day 14, shown as % relative growth as compared to control of H1299-7 cells treated with 0, 5 or 10 MBq/mL LuTate alone, or in combination with 0.5 μM or 1 μM of AZD-7648.

AZD-7648 purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2023 Oct 18;24(20):15331. [Abstract]

Customer Validation
Log dose–response viability curve of AZD-7648 after 24 or 48 (KG-1*) hours of treatment.

AZD-7648 purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2023 Oct 18;24(20):15331. [Abstract]

Customer Validation
Analysis of cell death induced by AZD-7648 (AZD，50-200 μM) in CML and AML cell lines after 24 or 48 (KG-1) hours of treatment.The type of cell death was identified using annexin V/propidium iodide staining and analyzed using flow cytometry. Data are expressed as a percentage (%) of viable, early apoptosis, late apoptosis/necrotic, and necrotic cells and represent mean ± SEM of 5 independent experiments. Statistical analyses were performed by comparison with control, using one-way ANOVA and Dunnett’s multiple comparisons test, Kruskal–Wallis and Dunn’s multiple comparisons test, unpaired t-test, or Mann–Whitney test.

AZD-7648 purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2023 Oct 18;24(20):15331. [Abstract]

Customer Validation
Analysis of cell death induced by AZD-7648 (AZD, 50-200 μM) in CML and AML cell lines after 24 or 48 (KG-1) hours of treatment. Cell morphology was observed by light microscopy (amplification: 1000×), and the most representative image was selected.

AZD-7648 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2022 Sep 8;13(1):5295. [Abstract]

Customer Validation
HEK 293T DSB-Spectrum_V3 cells were transfected with Cas9 and an sgRNA targeting either AAVS1 or BFP, followed by treatment with the DNA-PKcs inhibitors M3841 (2 µM) or AZD7648 (2 µM). At 72h after Cas9 transfection cells were analyzed by flow cytometry (n=4; mean ± SEM; One-way ANOVA, post-hoc Dunnett's).